ANL 11.20 Decreased By ▼ -0.25 (-2.18%)
ASC 9.71 Decreased By ▼ -0.09 (-0.92%)
ASL 12.00 Increased By ▲ 0.65 (5.73%)
AVN 80.00 Increased By ▲ 1.70 (2.17%)
BOP 5.94 Increased By ▲ 0.11 (1.89%)
CNERGY 5.70 Increased By ▲ 0.16 (2.89%)
FFL 6.85 Decreased By ▼ -0.12 (-1.72%)
FNEL 6.26 Increased By ▲ 0.11 (1.79%)
GGGL 12.10 Decreased By ▼ -0.05 (-0.41%)
GGL 16.89 Increased By ▲ 0.07 (0.42%)
GTECH 9.45 Decreased By ▼ -0.20 (-2.07%)
HUMNL 7.00 Increased By ▲ 0.35 (5.26%)
KEL 2.68 Increased By ▲ 0.12 (4.69%)
KOSM 3.09 Increased By ▲ 0.09 (3%)
MLCF 27.50 Increased By ▲ 0.25 (0.92%)
PACE 3.09 Decreased By ▼ -0.01 (-0.32%)
PIBTL 5.99 Decreased By ▼ -0.12 (-1.96%)
PRL 17.58 Decreased By ▼ -0.30 (-1.68%)
PTC 7.62 Decreased By ▼ -0.53 (-6.5%)
SILK 1.29 Decreased By ▼ -0.14 (-9.79%)
SNGP 27.40 Increased By ▲ 1.31 (5.02%)
TELE 11.64 Decreased By ▼ -0.12 (-1.02%)
TPL 9.90 Increased By ▲ 0.01 (0.1%)
TPLP 18.62 Increased By ▲ 0.94 (5.32%)
TREET 29.70 Decreased By ▼ -0.40 (-1.33%)
TRG 81.11 Decreased By ▼ -0.57 (-0.7%)
UNITY 22.48 Decreased By ▼ -0.79 (-3.39%)
WAVES 13.45 Decreased By ▼ -0.05 (-0.37%)
WTL 1.56 Decreased By ▼ -0.04 (-2.5%)
YOUW 5.09 Decreased By ▼ -0.01 (-0.2%)
BR100 4,262 Increased By 29.5 (0.7%)
BR30 15,499 Increased By 12.7 (0.08%)
KSE100 42,861 Increased By 319.7 (0.75%)
KSE30 16,276 Increased By 133.1 (0.82%)
World

EU nears deal with Valvena for Covid-19 vaccine

  • The EU has already signed contracts with AstraZeneca, Johnson & Johnson, Sanofi-GSK, Pfizer-BioNTech, CureVac, and Moderna.
12 Jan, 2021

BRUSSELS: The European Commission announced on Tuesday that it has concluded exploratory talks with Franco-Austrian biotechnology laboratory Valneva for the possible purchase of up to 60 million doses of its Covid-19 vaccine.

The EU executive has already signed contracts with six other laboratories and is also in discussions with US firm Novavax to secure 200 million doses.

Once the negotiations with Novavax and Valneva are completed, Europe would have contracts with eight different laboratories for more than 2.5 billion doses.

"By doing so, we can maximise our chances that all citizens will have access to safe and effective vaccines by the end of 2021," said European Health Commissioner Stella Kyriakides.

The EU said the planned contract with Valneva would allow a collective purchase by all 27 EU member states of 30 million doses initially, with an option for an additional 30 million.

Valneva's vaccine was developed using a technology based on inactivated viruses, as opposed to the mRNA method used by Pfizer/BioNTech and Moderna.

Valneva announced the start of human clinical trials in mid-December, and doses have already been ordered by the UK.

An EU authorisation is expected in the final months of this year.

The EU has already signed contracts with AstraZeneca, Johnson & Johnson, Sanofi-GSK, Pfizer-BioNTech, CureVac, and Moderna.

So far, only the Pfizer-BioNTech and Moderna vaccines have been approved by the European Medicines Agency (EMA). The European regulator is to review the AstraZeneca vaccine in late January.

Comments

Comments are closed.